Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.
Immunocytochemistry was used to analyze the expression of the Fas ligand (FasL) in sixty-four children with newly diagnosed acute lymphoblastic leukemia (ALL). FasL expression was detected in 55 of 64 children (86%). Children with newly diagnosed ALL and FasL expression exhibited longer relapse-free and overall survival times under chemotherapy than did patients who did not express the Fas ligand. These data suggest that Fas/FasL mediated signaling may play a general role in the cytotoxicity of anticancer drugs.
Volm
M
M
German Cancer Research Center, Department of Oncological Diagnostics and Therapy, Heidelberg, Germany.
Zintl
F
F
Sauerbrey
A
A
Koomägi
R
R
D015153:Blotting, Western; D002648:Child; D018572:Disease-Free Survival; D053222:Fas Ligand Protein; D006801:Humans; D007150:Immunohistochemistry; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism*; D011379:Prognosis; D013997:Time Factors
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins